✦ LIBER ✦

O.10 Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)

✍ Scribed by Seymour, M.T.; Maughan, T.S.; Wasan, H.S.; Brewster, A.E.; Shepherd, S.F.; O'Mahoney, M.S.; May, B.R.; Thompson, L.C.; Meade, ; Langley, R.E.

Book ID: 122801474
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 75 KB
Volume: 64
Category: Article
ISSN: 1040-8428
DOI: 10.1016/S1040-8428(13)70169-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

8LB Chemotherapy choices and doses in fr

8LB Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)

✍ M.T. Seymour; T.S. Maughan; H.S. Wasan; A.E. Brewster; S.F. Shepherd; M.S. O'Mah 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Chemotherapy options in elderly and frai

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

✍ Matthew T Seymour; Lindsay C Thompson; Harpreet S Wasan; Gary Middleton; Alison 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 308 KB

Different strategies of sequential and c

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

✍ Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 201 KB

Bevacizumab is equally effective and no

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C

✍ Price, T. J.; Zannino, D.; Wilson, K.; Simes, R. J.; Cassidy, J.; Van Hazel, G. 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 238 KB